87 related articles for article (PubMed ID: 25201188)
1. Cooperation of p53 mutations with other oncogenic alterations in cancer.
Girardini JE; Walerych D; Del Sal G
Subcell Biochem; 2014; 85():41-70. PubMed ID: 25201188
[TBL] [Abstract][Full Text] [Related]
2. Disarming mutant p53 oncogenic function.
Girardini JE; Marotta C; Del Sal G
Pharmacol Res; 2014 Jan; 79():75-87. PubMed ID: 24246451
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional regulation by mutant p53 and oncogenesis.
Santoro R; Strano S; Blandino G
Subcell Biochem; 2014; 85():91-103. PubMed ID: 25201190
[TBL] [Abstract][Full Text] [Related]
4. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.
Adhikari AS; Iwakuma T
Fukuoka Igaku Zasshi; 2009 Jun; 100(6):217-28. PubMed ID: 19670804
[TBL] [Abstract][Full Text] [Related]
6. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
7. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression.
Calistri D; Rengucci C; Seymour I; Lattuneddu A; Polifemo AM; Monti F; Saragoni L; Amadori D
J Cell Physiol; 2005 Aug; 204(2):484-8. PubMed ID: 15702478
[TBL] [Abstract][Full Text] [Related]
8. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Sato M; Vaughan MB; Girard L; Peyton M; Lee W; Shames DS; Ramirez RD; Sunaga N; Gazdar AF; Shay JW; Minna JD
Cancer Res; 2006 Feb; 66(4):2116-28. PubMed ID: 16489012
[TBL] [Abstract][Full Text] [Related]
9. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
10. p53 mutants without a functional tetramerisation domain are not oncogenic.
Chène P; Bechter E
J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694
[TBL] [Abstract][Full Text] [Related]
11. The p53 tumor suppressor gene and gene product.
Levine AJ
Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A; Rotter V
Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
[TBL] [Abstract][Full Text] [Related]
13. P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis.
Chang KW; Sarraj S; Lin SC; Tsai PI; Solt D
Carcinogenesis; 2000 Jul; 21(7):1441-51. PubMed ID: 10874024
[TBL] [Abstract][Full Text] [Related]
14. p53: balancing tumour suppression and implications for the clinic.
Buganim Y; Rotter V
Eur J Cancer; 2009 Sep; 45 Suppl 1():217-34. PubMed ID: 19775621
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
16. [Point mutations of N-ras oncogene and abnormal expression of rasp21, p53 proteins in orbital rhabdomyosarcoma].
Zhang H; Song G; Zhang S; Chang J; Zhang W; Yu H
Zhonghua Yan Ke Za Zhi; 2000 Jul; 36(4):267-9, 16. PubMed ID: 11853610
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
Olive KP; Tuveson DA; Ruhe ZC; Yin B; Willis NA; Bronson RT; Crowley D; Jacks T
Cell; 2004 Dec; 119(6):847-60. PubMed ID: 15607980
[TBL] [Abstract][Full Text] [Related]
18. Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast.
Flaman JM; Robert V; Lenglet S; Moreau V; Iggo R; Frebourg T
Oncogene; 1998 Mar; 16(10):1369-72. PubMed ID: 9546439
[TBL] [Abstract][Full Text] [Related]
19. Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke.
De Flora S; Balansky RM; D'Agostini F; Izzotti A; Camoirano A; Bennicelli C; Zhang Z; Wang Y; Lubet RA; You M
Cancer Res; 2003 Feb; 63(4):793-800. PubMed ID: 12591728
[TBL] [Abstract][Full Text] [Related]
20. The role of mutant p53 in human cancer.
Goh AM; Coffill CR; Lane DP
J Pathol; 2011 Jan; 223(2):116-26. PubMed ID: 21125670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
